

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**GENERTEC UNIVERSAL MEDICAL GROUP
COMPANY LIMITED**

通用環球醫療集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 2666)

**POLL RESULTS OF THE ANNUAL GENERAL MEETING
HELD ON 7 JUNE 2024**

At the annual general meeting (the “AGM”) of Genertec Universal Medical Group Company Limited 通用環球醫療集團有限公司 (the “Company”) held on 7 June 2024, all the proposed resolutions as set out in the notice of the AGM dated 16 May 2024 were duly passed by the shareholders of the Company by way of poll.

The poll results taken at the AGM are as follows:

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
1.	To receive and consider the audited consolidated financial statements of the Company and the reports of the directors of the Company (the “Directors”) and auditors of the Company (the “Auditors”) for the year ended 31 December 2023.	937,277,699 (98.92 %)	10,186,030 (1.08 %)
2.	To declare a final dividend of HK\$0.35 per share for the year ended 31 December 2023.	947,463,699 (100.00 %)	530 (0.00 %)
3(a).	To re-elect Mr. Chen Shisu as Director.	910,791,508 (96.13 %)	36,672,721 (3.87 %)
3(b).	To re-elect Ms. Wang Lin as Director.	930,990,324 (98.26 %)	16,473,905 (1.74 %)
3(c).	To re-elect Mr. Xu Ming as Director.	925,806,447 (97.71 %)	21,657,772 (2.29 %)
3(d).	To re-elect Mr. Zhu Ziyang as Director.	925,310,647 (97.66 %)	22,153,582 (2.34 %)
3(e).	To re-elect Mr. Li Yinquan as Director.	904,069,270 (95.42 %)	43,394,949 (4.58 %)

Ordinary Resolutions		Number of Votes (Approximate %)	
		For	Against
4.	To authorise the board of Directors (the “ Board ”) to fix the Directors’ remuneration.	943,169,629 (99.55 %)	4,294,600 (0.45 %)
5.	To re-appoint Ernst & Young as the Auditors and to authorise the Board to fix their remuneration.	944,956,494 (99.74 %)	2,507,735 (0.26 %)
6.	To grant a general mandate to the Directors to buy back shares of the Company not exceeding 10% of the total number of issued shares of the Company as at the date of passing of this resolution.	945,127,494 (99.75 %)	2,336,735 (0.25 %)
7.	To grant a general mandate to the Directors to issue, allot and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company as at the date of passing of this resolution.	833,430,389 (87.96 %)	114,033,840 (12.04 %)
8.	To extend the general mandate granted to the Directors to issue, allot and deal with additional shares in the capital of the Company by adding the aggregate number of the shares bought back by the Company.	834,666,568 (88.09 %)	112,797,661 (11.91 %)
9.	To consider and approve the continuing connected transactions under the 2024 Finance Lease Framework Agreement (as defined in the circular of the Company dated 16 May 2024 (the “ Circular ”)) and the proposed annual caps thereunder for the three years ending 31 December 2026 (as set out in the Circular).	299,984,997 (100.00 %)	532 (0.00 %)

As stated in the Circular, GT-PRC is the controlling shareholder holding approximately 39.68% of the total issued share capital of the Company (i.e., 750,651,700 shares). As such, GT-PRC and its associates had abstained from voting on the ordinary resolution approving the continuing connected transactions under the 2024 Finance Lease Framework Agreement and the proposed annual caps thereunder at the AGM. GT-PRC and its associates were entitled to vote on the other resolutions at the AGM.

As at the date of the AGM, the total number of shares of the Company in issue was 1,891,539,661 shares. Accordingly, the total number of shares entitling the holders thereof to attend and vote on approving the continuing connected transactions under the 2024 Finance Lease Framework Agreement and the proposed annual caps thereunder at the AGM was 1,140,887,961, and the total number of shares entitling the holders thereof to attend and vote on the other resolutions at the AGM was 1,891,539,661.

Saved as disclosed above, there were no restrictions on any shareholders to cast votes on any of the resolutions proposed at the AGM.

Mr. Chen Shisu and Ms. Wang Lin, being the executive Directors, Mr. Xu Ming being the non-executive Director, and Mr. Chow Siu Lui and Mr. Li Yinquan, being the independent non-executive Directors attended the AGM in person. Mr. Wang Wenbing, being the executive Director, Mr. Chan Kai Kong, Mr. Tong Chaoyin and Mr. Zhu Ziyang, being the non-executive Directors, and Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas, being the independent non-executive Directors, attended the AGM by way of video conference.

The Company's share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer for the vote-taking at the AGM.

For and on behalf of the Board
Genertec Universal Medical Group Company Limited
通用環球醫療集團有限公司
Chen Shisu
Chairman of the Board

Hong Kong, 7 June 2024

As at the date of this announcement, the executive Directors are Mr. Chen Shisu (Chairman), Mr. Wang Wenbing and Ms. Wang Lin; the non-executive Directors are Mr. Chan Kai Kong (Vice-chairman), Mr. Tong Chaoyin, Mr. Xu Ming and Mr. Zhu Ziyang; and the independent non-executive Directors are Mr. Li Yinquan, Mr. Chow Siu Lui, Mr. Xu Zhiming and Mr. Chan, Hiu Fung Nicholas.